Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval

TARRYTOWN, N.Y.andPARIS,March 28, 2017/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi will hold a conference call for the financial community to discuss the U.S. Food and Drug Administration approval of DUPIXENT® (dupilumab). The conference call will take place today,March 28, 2017, at4pm ET/10pm CEST.

The conference call will include a presentation followed by a Q&A session and will be accessible through an audio webcast atwww.regeneron.comandwww.sanofi.com, and also via the following telephone numbers:

U.S.: +1 (888) 660 6127France: +33 (0) 8 00 90 93 22UK: +44 (0) 800 028 8438International: +1 (973) 890 8355Access code: 92138426

A replay of the conference call and webcast will be archived on the Companies' websites.

About Regeneron Pharmaceuticals, Inc.Regeneron (NASDAQ:REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol, atopic dermatitis and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visitwww.regeneron.comor follow @Regeneron on Twitter.

About SanofiSanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed inParis(EURONEXT: SAN) and inNew York (NYSE:SNY).

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

Tel: + 1 (914) 847-3836

Tel: +1 (914) 847-5126

Mobile: +1 (914) 450-6677

[email protected]

[email protected]

Tel: 908-981-8745

Tel: +33 (0) 1 53 77 94 69

[email protected]

[email protected]

Tel: +1 (908) 981-6486

Mobile: +1 (908) 247-6006

[email protected]